论文部分内容阅读
About 15%-30% of women with breast cancer have tumors that lack cell surface receptors for estrogen, progesterone and HER2/neu, that are called triple negative breast cancer (TNBC).Traditionally these tumors are treated with cytotoxic chemotherapy, and no identifiable targeted therapies are available.While only a small percentage of these tumors (about 30%) have mutations in the DNA-repair gene BRCA, patients with TNBC tend to have and aggressive behavior and develop metastases early.It has been hypothesized that markers of high risk in TNBC without BRCA mutations may instead have down-regulated BRCA expression due to specific gene promoter rnethylation.